Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice

The possible mechanism through which IL-35 and decitabine treatment increased the survival of graft tissues is to enhance the proliferation of CD4+CD25+ Treg cells and suppress the generation and function of effector T cells. Thus, IL-35 gene therapy combined with decitabine provides a novel approach to induce transplantation tolerance.